Frankfurt
08.01.26 | 08:59
5,800 Euro
-3,33 % -0,200
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,800 | 6,150 | 12:45 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| Mi | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 | 110 | GlobeNewswire (Europe) | Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the... ► Artikel lesen | |
| 31.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.12.25 | ASCENTAGE-B (06855): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 30.12.25 | ASCENTAGE-B (06855): (1) CHANGE IN COMPOSITION OF NOMINATION COMMITTEE; (2) APPOINTMENT OF LEAD INDEPENDENT NON-EXECUTIVE DIRECTOR; (3) ESTABLISHMENT ... | 2 | HKEx | ||
| 17.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 09.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL: ASH 2025 | Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment | 1 | GlobeNewswire (USA) | ||
| 09.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL: ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60% | 2 | GlobeNewswire (USA) | ||
| ASCENTAGE PHARMA GROUP Aktie jetzt für 0€ handeln | |||||
| 09.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL: ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP | 1 | GlobeNewswire (USA) | ||
| 08.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL: ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Exposed Patients with Myeloid Malignances | 1 | GlobeNewswire (USA) | ||
| 06.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting | 80 | GlobeNewswire (Europe) | Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility... ► Artikel lesen | |
| 05.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.12.25 | Ascentage Gets Regulatory Clearance In The US And Europe To Conduct POLARIS-1 Trial | 2 | RTTNews | ||
| 05.12.25 | Ascentage Pharma To Launch Global Phase III Study Of Olverembatinib In Ph+ ALL | 269 | AFX News | BEIJING (dpa-AFX) - Ascentage Pharma Group International (AAPG, 6855.HK) announced that it received clearance from both the US Food and Drug Administration (FDA) and the European Medicines Agency... ► Artikel lesen | |
| 05.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA | 117 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company... ► Artikel lesen | |
| 05.12.25 | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA ANNOUNCES GLOBAL REGISTRATIONAL PHASE III STUDY OF OLVEREMBATINIB IN FIRST-LINE TREATMENT ... | 3 | HKEx | ||
| 01.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025 | 1 | GlobeNewswire (USA) | ||
| 28.11.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 27.11.25 | ASCENTAGE-B (06855): FURTHER GRANT OF AWARDS UNDER THE 2022 RSU SCHEME; AND GRANT OF OPTIONS UNDER THE POST IPO SHARE OPTION SCHEME | - | HKEx | ||
| 25.11.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature's Signal Transduction and Targeted ... | 525 | GlobeNewswire (Europe) | Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX:... ► Artikel lesen |
1 2 3 4 Weiter >>
61 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MONTE ROSA THERAPEUTICS | 23,280 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | |
| NUVALENT | 106,82 | +9,90 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,730 | 0,00 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,270 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| ERASCA | 5,170 | 0,00 % | Erasca stock pulls back after 25% jump, Stifel cites competitor data | ||
| ALUMIS | 17,920 | 0,00 % | Alumis prices $300M upsized public offering | ||
| AVIDITY BIOSCIENCES | 72,37 | +0,17 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 76,69 | 0,00 % | Wolfe Research stuft Kymera Therapeutics wegen fehlender Impulse herab | ||
| RECURSION PHARMACEUTICALS | 4,860 | 0,00 % | Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates | ||
| TANGO THERAPEUTICS | 11,790 | 0,00 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Appoints Sung Lee to Board of Directors | ||
| PRAXIS PRECISION MEDICINES | 292,53 | 0,00 % | Praxis Precision Prices $575 Mln Public Offering At $260/shr | ||
| ADMA BIOLOGICS | 18,820 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,680 | 0,00 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,390 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 52,88 | 0,00 % | Regencell Bioscience is the top performing pharma stock YTD |
ASCENTAGE PHARMA GROUP INTERNATIONAL gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -3,33 % bei einem Aktienkurs von 5,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL finden Sie auf Wallstreet Online.